HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use TYKERB safely and effectively. See full prescribing information for TYKERB.

TYKERB® (lapatinib) tablets Initial U.S. Approval: 2007

---- RECENT MAJOR CHANGES -----Month YEAR

Interstitial lung disease and pneumonitis. (5.4) -----INDICATIONS AND USAGE------

TYKERB, a kinase inhibitor, is indicated in combination with capecitabine, for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress HER2 and who have received prior therapy including an anthracycline, a taxane, and trastuzumab. (1)

----- DOSAGE AND ADMINISTRATION ----The recommended dosage of TYKERB is 1,250 mg (5 tablets) given orally once daily on Days 1-21 continuously in combination with capecitabine 2,000 mg/m²/day (administered orally in 2 doses approximately 12 hours apart) on Days 1-14 in a repeating 21 day cycle. (2.1)

- TYKERB should be taken at least one hour before or one hour after a meal. However, capecitabine should be taken with food or within 30 minutes after food. (2.1)
- TYKERB should be taken once daily. Do not divide daily doses of TYKERB. (2.1, 12.3)
- Modify dose for cardiac and other toxicities, severe hepatic impairment, and CYP3A4 drug interactions. (2.2)

----- DOSAGE FORMS AND STRENGTHS ------250 mg tablets (3)

-----CONTRAINDICATIONS -----None. (4)

------ WARNINGS AND PRECAUTIONS------

Decreases in left ventricular ejection fraction have been reported. Confirm normal LVEF before starting TYKERB and continue evaluations during treatment. (5.1)

- Dose reduction in patients with severe hepatic impairment should be • considered. (2.2, 5.2, 8.7)
- Diarrhea, including severe diarrhea, has been reported during treatment. Manage with anti-diarrheal agents, and replace fluids and electrolytes if severe. (5.3)
- Lapatinib has been associated with interstitial lung disease and pneumonitis. Discontinue TYKERB if patients experience severe pulmonary symptoms. (5.4)
- Lapatinib prolongs the QT interval in some patients. Consider ECG and electrolyte monitoring. (5.5)
- Fetal harm can occur when administered to a pregnant woman. Women should be advised not to become pregnant when taking TYKERB. (5.6) ----- ADVERSE REACTIONS ------

The most common (>20%) adverse reactions during treatment with TYKERB plus capecitabine were diarrhea, palmar-plantar erythrodysesthesia, nausea, rash, vomiting, and fatigue. (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact GlaxoSmithKline at 1-888-825-5249 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

--DRUG INTERACTIONS ---

- TYKERB is likely to increase exposure to concomitantly administered drugs which are metabolized by CYP3A4 or CYP2C8. (7.1)
- Avoid strong CYP3A4 inhibitors. If unavoidable, consider dose reduction of TYKERB in patients coadministered a strong CYP3A4 inhibitor. (2.2, 7.2)
- Avoid strong CYP3A4 inducers. If unavoidable, consider gradual dose increase of TYKERB in patients coadministered a strong CYP3A4 inducer. (2.2, 7.2)

See 17 for PATIENT COUNSELING INFORMATION and FDAapproved patient labeling.

Revised: Month YEAR TKB:XPI

USE IN SPECIFIC POPULATIONS 8

- 8.1 Pregnancy
- Nursing Mothers 8.3
- Pediatric Use 8.4
- Geriatric Use 8.5
- **Renal Impairment** 8.6
- Hepatic Impairment 8.7

10 OVERDOSAGE

- DESCRIPTION 11
- 12 **CLINICAL PHARMACOLOGY**
 - Mechanism of Action 12.1
 - 12.3 Pharmacokinetics
 - QT Prolongation 12.4
- 13 NONCLINICAL TOXICOLOGY
 - Carcinogenesis, Mutagenesis, Impairment of 13.1 Fertility
- 14 CLINICAL STUDIES
- HOW SUPPLIED/STORAGE AND HANDLING 16
- 17 PATIENT COUNSELING INFORMATION
 - Decreased Left Ventricular Ejection Fraction 17.1
 - 172 Diarrhea
 - 17.3 **Drug Interactions**
 - 17.4 Food
 - 17.5 **Divided Dosing**
 - FDA-Approved Patient Labeling 17.6

*Sections or subsections omitted from the full prescribing information are not listed.

FULL PRESCRIBING INFORMATION: CONTENTS*

INDICATIONS AND USAGE 2

- DOSAGE AND ADMINISTRATION
 - Recommended Dosing 2.1
- Dose Modification Guidelines 2.2
- 3 DOSAGE FORMS AND STRENGTHS

CONTRAINDICATIONS 4

- WARNINGS AND PRECAUTIONS 5
 - **Decreased Left Ventricular Ejection Fraction** 51
 - 5.2 Patients with Severe Hepatic Impairment
 - 5.3 Diarrhea
 - 5.4 Interstitial Lung Disease/Pneumonitis
 - QT Prolongation 5.5
 - 5.6 Pregnancy

ADVERSE ŘEACTIONS 6

- Clinical Trials Experience 6.1 7
 - DRUG INTERACTIONS
 - Effects of Lapatinib on Drug Metabolizing 7.1
 - Enzymes and Drug Transport Systems
 - Drugs that Inhibit or Induce Cytochrome P450 7.2 3A4 Enzymes
 - Drugs that Inhibit Drug Transport Systems 7.3
 - Other Chemotherapy Agents 7.4

1 FULL PRESCRIBING INFORMATION

2 1 INDICATIONS AND USAGE

TYKERB is indicated in combination with capecitabine for the treatment of patients with
advanced or metastatic breast cancer whose tumors overexpress HER2 and who have received
prior therapy including an anthracycline, a taxane, and trastuzumab.

6 2 DOSAGE AND ADMINISTRATION

7 2.1 Recommended Dosing

8 The recommended dose of TYKERB is 1,250 mg (5 tablets) given orally once daily on 9 Days 1-21 continuously in combination with capecitabine 2,000 mg/m²/day (administered orally 10 in 2 doses approximately 12 hours apart) on Days 1-14 in a repeating 21 day cycle. TYKERB 11 should be taken at least one hour before or one hour after a meal. The dose of TYKERB should 12 be once daily; dividing the daily dose is not recommended [see Clinical Pharmacology (12.3)].

13 Capecitabine should be taken with food or within 30 minutes after food. If a day's dose is

14 missed, the patient should not double the dose the next day. Treatment should be continued until

15 disease progression or unacceptable toxicity occurs.

16 **2.2 Dose Modification Guidelines**

17 <u>Cardiac Events:</u> TYKERB should be discontinued in patients with a decreased left 18 ventricular ejection fraction (LVEF) that is Grade 2 or greater by NCI Common Terminology 19 Criteria for Adverse Events (NCI CTCAE) and in patients with an LVEF that drops below the 20 institution's lower limit of normal *[see Warnings and Precautions (5.1) and Adverse Reactions* 21 (6.1)]. TYKERB may be restarted at a reduced dose (1,000 mg/day) after a minimum of 2 weeks 22 if the LVEF recovers to normal and the patient is asymptomatic.

<u>Hepatic Impairment:</u> Patients with severe hepatic impairment (Child-Pugh Class C) should have their dose of TYKERB reduced. A dose reduction to 750 mg/day in patients with severe hepatic impairment is predicted to adjust the area under the curve (AUC) to the normal range and should be considered. However, there is no clinical data with this dose adjustment in patients with severe hepatic impairment.

28 Concomitant Strong CYP3A4 Inhibitors: The concomitant use of strong CYP3A4

29 inhibitors should be avoided (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir,

30 indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconazole). Grapefruit

31 may also increase plasma concentrations of lapatinib and should be avoided. If patients must be

32 coadministered a strong CYP3A4 inhibitor, based on pharmacokinetic studies, a dose reduction

33 to 500 mg/day of lapatinib is predicted to adjust the lapatinib AUC to the range observed without

- 34 inhibitors and should be considered. However, there are no clinical data with this dose
- 35 adjustment in patients receiving strong CYP3A4 inhibitors. If the strong inhibitor is

37	dose i	s adjusted upward to the indicated dose. [See Drug Interactions (7.2).]
38		Concomitant Strong CYP3A4 Inducers: The concomitant use of strong CYP3A4
39	induce	ers should be avoided (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin,
40	rifape	ntin, phenobarbital, St. John's Wort). If patients must be coadministered a strong CYP3A4
41	induce	er, based on pharmacokinetic studies, the dose of lapatinib should be titrated gradually
42	from	1,250 mg/day up to 4,500 mg/day based on tolerability. This dose of lapatinib is predicted
43	to adj	ust the lapatinib AUC to the range observed without inducers and should be considered.
44	Howe	ver, there are no clinical data with this dose adjustment in patients receiving strong
45	CYP3	A4 inducers. If the strong inducer is discontinued the lapatinib dose should be reduced to
46	the in	dicated dose. [See Drug Interactions (7.2).]
47		Other Toxicities: Discontinuation or interruption of dosing with TYKERB may be
48	consid	dered when patients develop ≥Grade 2 NCI CTC toxicity and can be restarted at
49	1,250	mg/day when the toxicity improves to Grade 1 or less. If the toxicity recurs, then
50	TYKE	ERB should be restarted at a lower dose (1,000 mg/day).
51		See manufacturer's prescribing information for capecitabine dosage adjustment
52	guide	lines in the event of toxicity.
53	3	DOSAGE FORMS AND STRENGTHS
54		250 mg tablets — oval, biconvex, orange, film-coated with GS XJG debossed on one
55	side.	
56	4	CONTRAINDICATIONS
57		None.
58		See manufacturer's prescribing information for capecitabine contraindications.
59	5	WARNINGS AND PRECAUTIONS
60	5.1	Decreased Left Ventricular Ejection Fraction
61		TYKERB has been reported to decrease LVEF [see Adverse Reactions (6.1)]. In the
62	rando	mized clinical trial, the majority (>60%) of LVEF decreases occurred within the first 9
63	weeks	s of treatment; however, data on long-term exposure are limited. Caution should be taken if
64	TYKE	ERB is to be administered to patients with conditions that could impair left ventricular
65	functi	on. LVEF should be evaluated in all patients prior to initiation of treatment with TYKERB
66	to ens	ure that the patient has a baseline LVEF that is within the institution's normal limits. LVEF
67	should	d continue to be evaluated during treatment with TYKERB to ensure that LVEF does not
68	declin	be below the institution's normal limits [see Dosage and Administration (2.2)].
69	5.2	Patients with Severe Hepatic Impairment
70		If TYKERB is to be administered to patients with severe hepatic impairment, dose
71	reduct	tion should be considered [see Dosage and Administration (2.2) and Use in Specific
72		(ations (8.7)].

discontinued, a washout period of approximately 1 week should be allowed before the lapatinib

73 **5.3 Diarrhea**

Diarrhea, including severe diarrhea, has been reported during treatment with TYKERB
 [see Adverse Reactions (6.1)]. Proactive management of diarrhea with anti-diarrheal agents is
 important. Severe cases of diarrhea may require administration of oral or intravenous electrolytes
 and fluids, and interruption or discontinuation of therapy with TYKERB.

78 **5.4**

79

Interstitial Lung Disease/Pneumonitis

Lapatinib has been associated with interstitial lung disease and pneumonitis in

80 monotherapy or in combination with other chemotherapies [see Adverse Reactions (6.1)].

Patients should be monitored for pulmonary symptoms indicative of interstitial lung disease or
pneumonitis. TYKERB should be discontinued in patients who experience pulmonary symptoms

- 83 indicative of interstitial lung disease/pneumonitis which are \geq Grade 3 (NCI CTCAE).
- 84 **5.5 QT Prolongation**

85 QT prolongation measured by automated machine-read evaluation of ECG was observed 86 in an uncontrolled, open-label dose escalation study of lapatinib in advanced cancer patients *[see* 87 *Clinical Pharmacology (12.4)*]. Lapatinib should be administered with caution to patients who 88 have or may develop prolongation of QTc. These conditions include patients with hypokalemia 89 or hypomagnesemia, with congenital long QT syndrome, patients taking anti-arrhythmic 90 medicines or other medicinal products that lead to OT prolongation, and cumulative high-dose 91 anthracycline therapy. Hypokalemia or hypomagnesemia should be corrected prior to lapatinib 92 administration. The prescriber should consider baseline and on-treatment electrocardiograms 93 with QT measurement.

94 5.6 Pregnancy

95 Pregnancy Category D

96 TYKERB can cause fetal harm when administered to a pregnant woman. In a study
97 where pregnant rats were dosed with lapatinib during organogenesis and through lactation, at a
98 dose of 120 mg/kg/day (approximately 6.4 times the human clinical exposure based on AUC),
99 91% of the pups had died by the fourth day after birth, while 34% of the 60 mg/kg/day pups were
100 dead. The highest no-effect dose for this study was 20 mg/kg/day (approximately equal to the
101 human clinical exposure based on AUC).

102 Lapatinib was studied for effects on embryo-fetal development in pregnant rats and 103 rabbits given oral doses of 30, 60, and 120 mg/kg/day. There were no teratogenic effects;

however, minor anomalies (left-sided umbilical artery, cervical rib, and precocious ossification)

- 105 occurred in rats at the maternally toxic dose of 120 mg/kg/day (approximately 6.4 times the
- 106 human clinical exposure based on AUC). In rabbits, lapatinib was associated with maternal
- 107 toxicity at 60 and 120 mg/kg/day (approximately 0.07 and 0.2 times the human clinical exposure,
- 108 respectively, based on AUC) and abortions at 120 mg/kg/day. Maternal toxicity was associated
- 109 with decreased fetal body weights and minor skeletal variations.
- There are no adequate and well-controlled studies with TYKERB in pregnant women.Women should be advised not to become pregnant when taking TYKERB. If this drug is used

during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus.

114 6 ADVERSE REACTIONS

115 **6.1 Clinical Trials Experience**

The safety of TYKERB has been evaluated in more than 3,500 patients in clinical trials.
The efficacy and safety of TYKERB in combination with capecitabine in breast cancer was
evaluated in 198 patients in a randomized, Phase 3 trial. *[See Clinical Studies (14).]* Adverse
reactions which occurred in at least 10% of patients in either treatment arm and were higher in
the combination arm are shown in Table 1.
Because clinical trials are conducted under widely varying conditions, adverse reaction

- Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
- 124 The most common adverse reactions (>20%) during therapy with TYKERB plus 125 capecitabine were gastrointestinal (diarrhea, nausea, and vomiting), dermatologic (palmar-126 plantar erythrodysesthesia and rash), and fatigue. Diarrhea was the most common adverse 127 reaction resulting in discontinuation of study medication.
- 128 The most common Grade 3 and 4 adverse reactions (NCI CTC v3) were diarrhea and 129 palmar-plantar erythrodysesthesia. Selected laboratory abnormalities are shown in Table 2. 130

	TYKERB					
	Capecitabine 2,000 mg/m ² /day (N = 198)			Capecitabine 2,500 mg/m²/day (N = 191)		
Reactions	All Grades [*] %	Grade 3 %	Grade 4 %	All Grades [*] %	Grade 3 %	Grade 4 %
Gastrointestinal disorders	70	70	70	/0	70	70
Diarrhea	65	13	1	40	10	0
Nausea	44	2	0	43	2	0
Vomiting	26	2	0	21	2	0
Stomatitis	14	0	0	11	<1	0
Dyspepsia	11	<1	0	3	0	0
Skin and subcutaneous tissue disorders						
Palmar-plantar erythrodysesthesia	53	12	0	51	14	0
$Rash^\dagger$	28	2	0	14	1	0
Dry skin	10	0	0	6	0	0
General disorders and administrative site conditions						
Mucosal inflammation	15	0	0	12	2	0
Musculoskeletal and connective tissue disorders						
Pain in extremity	12	1	0	7	<1	0
Back pain	11	1	0	6	<1	0
Respiratory, thoracic, and mediastinal disorders						
Dyspnea	12	3	0	8	2	0
Psychiatric disorders						
Insomnia	10	<1	0	6	0	0

131 **Table 1. Adverse Reactions Occurring in \geq10% of Patients**

132

^{*} National Cancer Institute Common Terminology Criteria for Adverse Events, version 3.

[†] Grade 3 dermatitis acneiform was reported in <1% of patients in TYKERB plus capecitabine

134 group.

		1,250 mg/d		~		. 2
	Capecitabin	<u>e 2,000 mg/</u>	Capecitabine 2,500 mg/m ² /day			
	All Grades [*]	Grade 3	Grade 4	All Grades [*]	Grade 3	Grade 4
Parameters	%	%	%	%	%	%
Hematologic						
Hemoglobin	56	<1	0	53	1	0
Platelets	18	<1	0	17	<1	<1
Neutrophils	22	3	<1	31	2	1
Hepatic						
Total Bilirubin	45	4	0	30	3	0
AST	49	2	<1	43	2	0
ALT	37	2	0	33	1	0

136 Table 2. Selected Laboratory Abnormalities

137 National Cancer Institute Common Terminology Criteria for Adverse Events, version 3.

138

139 Decreases in Left Ventricular Ejection Fraction: Due to potential cardiac toxicity

140 with HER2 (ErbB2) inhibitors, LVEF was monitored in clinical trials at approximately 8-week

141 intervals. LVEF decreases were defined as signs or symptoms of deterioration in left ventricular

142 cardiac function that are \geq Grade 3 (NCI CTCAE), or a \geq 20% decrease in left ventricular cardiac

143 ejection fraction relative to baseline which is below the institution's lower limit of normal.

144 Among 198 patients who received lapatinib/capecitabine combination treatment, 3 experienced

145 Grade 2 and one had Grade 3 LVEF adverse reactions (NCI CTC 3.0). [See Warnings and

146 Precautions (5.1).]

147 Interstitial Lung Disease/Pneumonitis: Lapatinib has been associated with interstitial lung disease and pneumonitis in monotherapy or in combination with other chemotherapies [see 148 149 Warnings and Precautions (5.4)].

150 7 DRUG INTERACTIONS

151 7.1 Effects of Lapatinib on Drug Metabolizing Enzymes and Drug Transport 152 **Systems**

153 Lapatinib inhibits CYP3A4 and CYP2C8 in vitro at clinically relevant concentrations. 154 Caution should be exercised and dose reduction of the concomitant substrate drug should be 155 considered when dosing lapatinib concurrently with medications with narrow therapeutic windows that are substrates of CYP3A4 or CYP2C8. Lapatinib did not significantly inhibit the 156 157 following enzymes in human liver microsomes: CYP1A2, CYP2C9, CYP2C19, and CYP2D6 or 158 UGT enzymes in vitro, however, the clinical significance is unknown. 159 Lapatinib inhibits human P-glycoprotein. If TYKERB is administered with drugs that are 160 substrates of Pgp, increased concentrations of the substrate drug are likely, and caution should be

161 exercised.

162 7.2 Drugs that Inhibit or Induce Cytochrome P450 3A4 Enzymes

163 Lapatinib undergoes extensive metabolism by CYP3A4, and concomitant administration

164 of strong inhibitors or inducers of CYP3A4 alter lapatinib concentrations significantly (see

- 165 <u>Ketoconazole</u> and <u>Carbamazepine</u> sections, below). Dose adjustment of lapatinib should be
- 166 considered for patients who must receive concomitant strong inhibitors or concomitant strong
- 167 inducers of CYP3A4 enzymes [see Dosage and Administration (2.2)].
- 168 Ketoconazole: In healthy subjects receiving ketoconazole, a CYP3A4 inhibitor, at
- 200 mg twice daily for 7 days, systemic exposure (AUC) to lapatinib was increased toapproximately 3.6-fold of control and half-life increased to 1.7-fold of control.
- 171 <u>Carbamazepine:</u> In healthy subjects receiving the CYP3A4 inducer, carbamazepine, at 172 100 mg twice daily for 3 days and 200 mg twice daily for 17 days, systemic exposure (AUC) to 173 lapatinib was decreased approximately 72%.

174 **7.3 Drugs that Inhibit Drug Transport Systems**

- 175 Lapatinib is a substrate of the efflux transporter P-glycoprotein (Pgp, ABCB1). If
- 176 TYKERB is administered with drugs that inhibit Pgp, increased concentrations of lapatinib are
- 177 likely, and caution should be exercised.
- 178 **7.4 Other Chemotherapy Agents**
- In a separate study, concomitant administration of lapatinib with capecitabine did notmeaningfully alter the pharmacokinetics of either agent (or the metabolites of capecitabine).
- 181 8 USE IN SPECIFIC POPULATIONS

182 8.1 Pregnancy

183 Pregnancy Category D [see Warnings and Precautions (5.6)].

184 8.3 Nursing Mothers

- 185 It is not known whether lapatinib is excreted in human milk. Because many drugs are 186 excreted in human milk and because of the potential for serious adverse reactions in nursing 187 infants from TYKERB, a decision should be made whether to discontinue nursing or to
- 188 discontinue the drug, taking into account the importance of the drug to the mother.

1898.4Pediatric Use

190

The safety and effectiveness of TYKERB in pediatric patients have not been established.

191 8.5 Geriatric Use

- 192 Of the total number of metastatic breast cancer patients in clinical studies of TYKERB in 193 combination with capecitabine (N = 198), 17% were 65 years of age and older, and 1% were 194 75 years of age and older. No overall differences in safety or effectiveness of the combination of 195 TYKERB and capecitabine were observed between these subjects and younger subjects, and 196 other reported clinical experience has not identified differences in responses between the elderly 197 and younger patients, but greater sensitivity of some older individuals cannot be ruled out. 198 **8.6 Penal Impairment**
- 198 8.6 Renal Impairment
- Lapatinib pharmacokinetics have not been specifically studied in patients with renalimpairment or in patients undergoing hemodialysis. There is no experience with TYKERB in

- 201 patients with severe renal impairment. However, renal impairment is unlikely to affect the
- 202 pharmacokinetics of lapatinib given that less than 2% (lapatinib and metabolites) of an
- administered dose is eliminated by the kidneys.

204 8.7 Hepatic Impairment


The pharmacokinetics of lapatinib were examined in subjects with moderate (n = 8) or severe (n = 4) hepatic impairment (Child-Pugh Class B/C, respectively) and in 8 healthy control subjects. Systemic exposure (AUC) to lapatinib after a single oral 100-mg dose increased approximately 14% and 63% in subjects with moderate and severe hepatic impairment, respectively. Administration of TYKERB in patients with severe hepatic impairment should be undertaken with caution due to increased exposure to the drug. A dose reduction should be considered for patients with severe hepatic impairment *[see Dosage and Administration (2.2)]*.

212 10 OVERDOSAGE

- There is no known antidote for overdoses of TYKERB. The maximum oral doses of lapatinib that have been administered in clinical trials are 1,800 mg once daily. More frequent ingestion of TYKERB could result in serum concentrations exceeding those observed in clinical trials and could result in increased toxicity. Therefore, missed doses should not be replaced and dosing should resume with the next scheduled daily dose.
- There has been a report of one patient who took 3,000 mg of TYKERB for 10 days. This patient had Grade 3 diarrhea and vomiting on Day 10. The event resolved following IV hydration and interruption of treatment with TYKERB and letrozole.
- Because lapatinib is not significantly renally excreted and is highly bound to plasma proteins, hemodialysis would not be expected to be an effective method to enhance the elimination of lapatinib.

224 **11 DESCRIPTION**

- 225 Lapatinib is a small molecule and a member of the 4-anilinoquinazoline class of kinase
- 226 inhibitors. It is present as the monohydrate of the ditosylate salt, with chemical name N-(3-
- 227 chloro-4-{[(3-fluorophenyl)methyl]oxy}phenyl)-6-[5-({[2-
- 228 (methylsulfonyl)ethyl]amino}methyl)-2-furanyl]-4-quinazolinamine bis(4-
- 229 methylbenzenesulfonate) monohydrate. It has the molecular formula $C_{29}H_{26}ClFN_4O_4S$
- $(C_7H_8O_3S)_2$ H₂O and a molecular weight of 943.5. Lapatinib ditosylate monohydrate has the
- 231 following chemical structure:



Lapatinib is a yellow solid, and its solubility in water is 0.007 mg/mL and in 0.1N HCl is 0.001 mg/mL at 25°C.

Each 250 mg tablet of TYKERB contains 405 mg of lapatinib ditosylate monohydrate, equivalent to 398 mg of lapatinib ditosylate or 250 mg lapatinib free base.

237 The inactive ingredients of TYKERB are: **Tablet Core:** Magnesium stearate,

238 microcrystalline cellulose, povidone, sodium starch glycolate. **Coating:** Orange film-coat:

239 FD&C yellow No. 6/sunset yellow FCF aluminum lake, hypromellose, macrogol/PEG 400,

240 polysorbate 80, titanium dioxide.

241 12 CLINICAL PHARMACOLOGY

242 **12.1** Mechanism of Action

243 Lapatinib is a 4-anilinoquinazoline kinase inhibitor of the intracellular tyrosine kinase 244 domains of both Epidermal Growth Factor Receptor (EGFR [ErbB1]) and of Human Epidermal 245 Receptor Type 2 (HER2 [ErbB2]) receptors (estimated K_i^{app} values of 3nM and 13nM, 246 respectively) with a dissociation half-life of \geq 300 minutes. Lapatinib inhibits ErbB-driven tumor

- 247 cell growth in vitro and in various animal models.
- An additive effect was demonstrated in an in vitro study when lapatinib and 5-FU (the active metabolite of capecitabine) were used in combination in the 4 tumor cell lines tested. The

250 growth inhibitory effects of lapatinib were evaluated in trastuzumab-conditioned cell lines.

251 Lapatinib retained significant activity against breast cancer cell lines selected for long-term

252 growth in trastuzumab-containing medium in vitro. These in vitro findings suggest non-cross-

253 resistance between these two agents.

254 **12.3 Pharmacokinetics**

Absorption: Absorption following oral administration of TYKERB is incomplete and
 variable. Serum concentrations appear after a median lag time of 0.25 hours (range 0 to
 1.5 hour). Peak plasma concentrations (C_{max}) of lapatinib are achieved approximately 4 hours

after administration. Daily dosing of TYKERB results in achievement of steady state within 6 to
7 days, indicating an effective half-life of 24 hours.

At the dose of 1,250 mg daily, steady state geometric mean (95% confidence interval) values of C_{max} were 2.43 mcg/mL (1.57 to 3.77 mcg/mL) and AUC were 36.2 mcg.hr/mL (23.4 to 56 mcg.hr/mL).

- 263Divided daily doses of TYKERB resulted in approximately 2-fold higher exposure at264steady state (steady state AUC) compared to the same total dose administered once daily.
- Systemic exposure to lapatinib is increased when administered with food. Lapatinib AUC values were approximately 3- and 4-fold higher (C_{max} approximately 2.5- and 3-fold higher) when administered with a low fat (5% fat-500 calories) or with a high fat (50% fat-1,000
- 268 calories) meal, respectively.
- <u>Distribution:</u> Lapatinib is highly bound (>99%) to albumin and alpha-1 acid
 glycoprotein. In vitro studies indicate that lapatinib is a substrate for the transporters breast
 cancer resistance protein (BCRP, ABCG2) and P-glycoprotein (Pgp, ABCB1). Lapatinib has also
 been shown in vitro to inhibit these efflux transporters, as well as the hepatic uptake transporter
 OATP 1B1, at clinically relevant concentrations.
- 274 <u>Metabolism:</u> Lapatinib undergoes extensive metabolism, primarily by CYP3A4 and 275 CYP3A5, with minor contributions from CYP2C19 and CYP2C8 to a variety of oxidated 276 metabolites, none of which accounts for more than 14% of the dose recovered in the feces or 277 10% of heartinib concentration in about
- 277 10% of lapatinib concentration in plasma.
- <u>Elimination:</u> At clinical doses, the terminal phase half-life following a single dose was
 14.2 hours; accumulation with repeated dosing indicates an effective half-life of 24 hours.
- Elimination of lapatinib is predominantly through metabolism by CYP3A4/5 with negligible (<2%) renal excretion. Recovery of parent lapatinib in feces accounts for a median of 27% (range 3 to 67%) of an oral dose.
- 283 <u>Effects of Age, Gender, or Race:</u> Studies of the effects of age, gender, or race on the 284 pharmacokinetics of lapatinib have not been performed.

285 **12.4 QT Prolongation**

The QT prolongation potential of lapatinib was assessed as part of an uncontrolled, openlabel dose escalation study in advanced cancer patients. Eighty-one patients received daily doses of lapatinib ranging from 175 mg/day to 1,800 mg/day. Serial ECGs were collected on Day 1 and Day 14 to evaluate the effect of lapatinib on QT intervals. Thirteen of the 81 subjects were found to have either QTcF (corrected QT by the Friedericia method) >480 msec or an increase in QTcF >60 msec by automated machine-read evaluation of ECG. Analysis of the data suggested a relationship between lapatinib concentration and the QTc interval.

293 13 NONCLINICAL TOXICOLOGY

294 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

- 295 Two-year carcinogenicity studies with lapatinib are ongoing.
- 296 Lapatinib was not clastogenic or mutagenic in the Chinese hamster ovary chromosome
- 297 aberration assay, microbial mutagenesis (Ames) assay, human lymphocyte chromosome
- aberration assay or the in vivo rat bone marrow chromosome aberration assay at single doses up
- to 2,000 mg/kg. However, an impurity in the drug product (up to 4 ppm or 8 mcg/day) was
- 300 genotoxic when tested alone in both in vitro and in vivo assays.

301 There were no effects on male or female rat mating or fertility at doses up to

302 120 mg/kg/day in females and 180 mg/kg/day in males (approximately 6.4 times and 2.6 times

303 the expected human clinical exposure based on AUC, respectively). The effect of lapatinib on

304 human fertility is unknown. However, when female rats were given oral doses of lapatinib during

305 breeding and through the first 6 days of gestation, a significant decrease in the number of live

fetuses was seen at 120 mg/kg/day and in the fetal body weights at ≥ 60 mg/kg/day

- 307 (approximately 6.4 times and 3.3 times the expected human clinical exposure based on AUC,
- 308 respectively).

309 14 CLINICAL STUDIES

The efficacy and safety of TYKERB in combination with capecitabine in breast cancer were evaluated in a randomized, Phase 3 trial. Patients eligible for enrollment had HER2 (ErbB2) over-expressing (IHC 3+ or IHC 2+ confirmed by FISH), locally advanced or metastatic breast cancer, progressing after prior treatment that included anthracyclines, taxanes, and trastuzumab.

315 Patients were randomized to receive either TYKERB 1,250 mg once daily (continuously) 316 plus capecitabine 2,000 mg/m²/day on Days 1-14 every 21 days, or to receive capecitabine alone at a dose of $2.500 \text{ mg/m}^2/\text{day}$ on Days 1-14 every 21 days. The endpoint was time to progression 317 318 (TTP). TTP was defined as time from randomization to tumor progression or death related to 319 breast cancer. Based on the results of a pre-specified interim analysis, further enrollment was 320 discontinued. Three hundred and ninety-nine (399) patients were enrolled in this study. The 321 median age was 53 years and 14% were older than 65 years. Ninety-one percent (91%) were 322 Caucasian. Ninety-seven percent (97%) had stage IV breast cancer, 48% were estrogen receptor+ 323 (ER+) or progesterone receptor+ (PR+), and 95% were ErbB2 IHC 3+ or IHC 2+ with FISH 324 confirmation. Approximately 95% of patients had prior treatment with anthracyclines, taxanes,

and trastuzumab.

Efficacy analyses four months after the interim analysis are presented in Table 3, Figure 1, and Figure 2.

329 **Table 3. Efficacy Results**

	Independent	Assessment*	Investigator Assessment		
	TYKERB		TYKERB		
	1,250 mg/day +		1,250 mg/day +		
	Capecitabine	Capecitabine	Capecitabine	Capecitabine	
	2,000 mg/m ² /day	2,500 mg/m ² /day	2,000 mg/m ² /day	2,500 mg/m ² /day	
	(N = 198)	(N = 201)	(N = 198)	(N = 201)	
Number of TTP events	82	102	121	126	
Median TTP, weeks	27.1	18.6	23.9	18.3	
(25 th , 75 th , Percentile),	(17.4, 49.4)	(9.1, 36.9)	(12.0, 44.0)	(6.9, 35.7)	
weeks					
Hazard Ratio	0.57		0.72		
(95% CI)	(0.43,	0.77)	(0.56, 0.92)		
p value	0.00013		0.00762		
Response Rate (%)	23.7	13.9	31.8	17.4	
(95% CI)	(18.0, 30.3)	(9.5, 19.5)	(25.4, 38.8)	(12.4, 23.4)	

 $330 \quad \text{TTP} = \text{Time to progression.}$


331 * The time from last tumor assessment to the data cut-off date was >100 days in approximately


30% of patients in the independent assessment. The pre-specified assessment interval was 42 or84 days.

334

335 Figure 1. Kaplan-Meier Estimates for Independent Review Panel-evaluated Time to

336 **Progression**





340	At the time of updated analysis, 30% of patients had died and the data for survival
341	analysis are not mature. Fifty-five patients (28%) in the TYKERB plus capecitabine group and
342	64 subjects (32%) in the capecitabine group had died.

343 16 HOW SUPPLIED/STORAGE AND HANDLING

- 344 The 250 mg tablets of TYKERB are oval, biconvex, orange, and film-coated with
- 345 GS XJG debossed on one side and are available in:
- 346 Bottles of 150 tablets: NDC 0173-0752-00
- 347 Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP
- 348 Controlled Room Temperature].

349 **17 PATIENT COUNSELING INFORMATION**

350 *See FDA-approved patient labeling (17.6).*

351 17.1 Decreased Left Ventricular Ejection Fraction

- 352 Patients should be informed that TYKERB has been reported to decrease left ventricular
- 353 ejection fraction which may result in shortness of breath, palpitations, and/or fatigue. Patients
- 354 should inform their physician if they develop these symptoms while taking TYKERB.
- 355 **17.2 Diarrhea**
- Patients should be informed that TYKERB often causes diarrhea which may be severe in
 some cases. Patients should be told how to manage and/or prevent diarrhea and to inform their
- 358 physician if severe diarrhea occurs during treatment with TYKERB.

359 **17.3 Drug Interactions**

TYKERB may interact with many drugs; therefore, patients should be advised to report
 to their healthcare provider the use of any other prescription or nonprescription medication or

- 362 herbal products.
- **363 17.4 Food**
- Patients should be informed of the importance of taking TYKERB at least one hour before or one hour after a meal, in contrast to capecitabine which should be taken with food or within 30 minutes after food.
- 367 17.5 Divided Dosing
- The dose of TYKERB should not be divided. Patients should be advised of the importance of taking TYKERB once daily, in contrast to capecitabine which is taken twice daily.
- 370 17.6 FDA-Approved Patient Labeling
- 371 Patient labeling is provided as a tear-off leaflet at the end of this full prescribing
- 372 information.373
- 374 TYKERB is a registered trademark of GlaxoSmithKline.
- 375

gsk GlaxoSmithKline

376

377 GlaxoSmithKline

- 378 Research Triangle Park, NC 27709
- 379
- 380 ©YEAR, GlaxoSmithKline. All rights reserved.

381	PHARMACIST - DETACH HERE AND GIVE INSTRUCTIONS TO PATIENT
382	
383	
384	PATIENT INFORMATION
385 386	TYKERB[®] (TIE-curb)
387	(lapatinib) tablets
388	
389	Read this leaflet before you start taking TYKERB and each time you get a refill. There may be
390	new information. This information does not take the place of talking with your doctor about your
391	medical condition or treatment.
392	
393	What is TYKERB?
394	TYKERB is used with the medicine capecitabine for the treatment of patients with advanced or
395	metastatic breast cancer that is HER2 positive, and who have already had certain other breast
396	cancer treatments.
397	
398	Before you start taking TYKERB , tell your doctor about all of your medical conditions,
399	including if you:
400	have heart problems.
401 402	 have liver problems. You may need a lower dose of TYKERB. are pregnant or may become pregnant. TYKERB may harm an unborn baby. If you become
402	• are pregnant or may become pregnant. TYKERB may harm an unborn baby. If you become pregnant during treatment with TYKERB, tell your doctor as soon as possible.
403	 are breastfeeding. It is not known if TYKERB passes into your breast milk or if it can harm
405	your baby. If you are a woman who has or will have a baby, talk with your doctor about the
406	best way to feed your baby.
407	
408	Tell your doctor about all the medicines you take, including prescription and nonprescription
409	medicines and herbal and dietary supplements. TYKERB and many other medicines may interact
410	with each other. Your doctor needs to know what medicines you take so he or she can choose the
411	right dose of TYKERB for you.
412	
413	Especially tell your doctor if you take:
414	• antibiotics and anti-fungals (drugs used to treat infections)
415	• HIV (AIDS) treatments
416	 anticonvulsant drugs (drugs used to treat seizures)
417	• calcium channel blockers (drugs used to treat certain heart disorders or high blood pressure)
418	• antidepressants
419	drugs used for stomach ulcers
420	• St. John's Wort or other herbal supplements

- 421 422 Know the medicines you take. Keep a list of your medicines with you to show your doctor. Do 423 not take other medicines during treatment with TYKERB without first checking with your 424 doctor. 425 426 Because TYKERB is given with another drug called capecitabine, you should also discuss with 427 your doctor or pharmacist any medicines that should be avoided when taking capecitabine. 428 429 How should I take TYKERB? 430 Take TYKERB exactly as your doctor has told you. TYKERB and capecitabine are taken in 431 21 day cycles. The usual dose of TYKERB is 1,250 mg (5 tablets) taken by mouth, one time 432 a day on days 1 to 21. Your doctor will tell you the dose of capecitabine you should take 433 and when you should take it. 434 TYKERB should be taken at least one hour before, or at least one hour after food. ٠ 435 • Do not eat or drink grapefruit products while taking TYKERB. 436 • Your doctor may adjust your dose of TYKERB depending on how you tolerate the 437 treatment. 438 If you forget to take your dose of TYKERB, take it as soon as you remember that day. If • 439 you miss a day, do not double your dose the next day. Just skip the missed dose. 440 441 What are the possible side effects of TYKERB? 442 Serious side effects include: 443 • heart problems
 - decreased pumping of blood from the heart
 - 445 abnormal heartbeat
 - 446 lung problems
 - severe diarrhea, which may lead to you becoming dehydrated
 - Call your doctor right away if you have palpitations, persistent cough, shortness of breath,
 or severe diarrhea.
 - 451

- 452 **Common side effects** of TYKERB in combination with capecitabine include:
- 453 diarrhea
- red, painful hands and feet
- 455 nausea
- 456 rash
- 457 vomiting
- 458 tiredness
- mouth sores
- loss of appetite

461 462	• indigestion
463 464	Tell your doctor about any side effect that gets serious or that does not go away.
465 466 467	These are not all the side effects with TYKERB. Ask your doctor or pharmacist for more information.
468 469 470	You may also get side effects from capecitabine. Talk to your doctor about possible side effects with capecitabine.
471	How should I store TYKERB tablets?
472 473	• Store TYKERB tablets at room temperature between 59° and 86°F (15° to 30°C). Keep the container closed tightly.
474 475	• Do not keep medicine that is out of date or that you no longer need. Be sure that if you throw any medicine away, it is out of the reach of children.
476 477	• Keep TYKERB and all medicines out of the reach of children.
478	General information about TYKERB
479 480 481	Medicines are sometimes prescribed for conditions that are not mentioned in patient information leaflets. Do not use TYKERB for any other condition for which it was not prescribed. Do not give TYKERB to other people, even if they have the same condition that you have. It may harm
481 482 483	them.
484 485 486 487 488	This leaflet summarizes the most important information about TYKERB. If you would like more information, talk with your doctor. You can ask your doctor or pharmacist for information about TYKERB that is written for health professionals. For more information you can call toll-free 1-888-825-5249.
489	What are the ingredients in TYKERB?
490	Active Ingredient: Lapatinib.
491	Inactive Ingredients: Tablet Core: Magnesium stearate, microcrystalline cellulose, povidone,
492	sodium starch glycolate. Coating: Orange film-coat: FD&C yellow #6/sunset yellow FCF
493 494	aluminum lake, hypromellose, macrogol/PEG 400, polysorbate 80, titanium dioxide.
495 496	TYKERB tablets are oval, biconvex, orange, film-coated with GS XJG printed on one side.
497	GSXJG

499 Revised: Month YEAR

- 500 TKB:XPIL
- 501
- 502 TYKERB is a registered trademark of GlaxoSmithKline.
- 503

gsk GlaxoSmithKline

- 504 505 GlaxoSmithKline
- 506 Research Triangle Park, NC 27709
- 507
- 508 ©YEAR, GlaxoSmithKline. All rights reserved.
- 509